LifeNet Health LifeSciences continues to lead the way in stem cell development by investigating human induced pluripotent stem cells (iPSC) as viable research solutions. iPSC, derived from human fibroblasts and osteoblasts, have been successfully differentiated into hepatocytes, cardiomyocytes, and neural crest cells. These human iPSC derivatives were differentiated through embryoid body formation and then adherent culture on LifeSciences’ proprietary human-derived extracellular matrix (ECM), HuGentraTM. The success of these cell models on human tissue-derived ECM will further advance discovery and development of new therapies.
